

ELITE PHARMACEUTICALS INC /DE/  
Form 8-K  
April 07, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

April 4, 2011

---

Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS, INC.

---

(Exact name of Company as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-15697  
(Commission  
File Number)

22-3542636  
(IRS Employer  
Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

---

(Address of principal executive offices)

(201) 750-2646

---

(Company's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events

On April 7, 2011, Elite Pharmaceuticals, Inc. (the “Company”) issued a press release to announce that the initial shipment of phentermine HCl 37.5 mg tablets was made to TAGI Pharma, a wholly owned subsidiary of Precision Dose, triggering a milestone payment under the License, Manufacturing and Supply Agreement.

A copy of the press release is being finished with this Current Report on Form 8-K as Exhibit 99.1, but is not incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

- a) Not applicable.
- b) Not applicable.
- c) Not applicable.
- d) Exhibits

Exhibit No. Exhibit

99.1 Press Release dated April 7, 2011

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 7, 2011

ELITE PHARMACEUTICALS,  
INC.

By: /s/ Chris Dick  
Name: Chris Dick  
Title: President and Chief Operating  
Officer

---